Cellular and molecular mechanisms of host resistance to Toxoplasma gondii

宿主抵抗弓形虫的细胞和分子机制

基本信息

  • 批准号:
    8616022
  • 负责人:
  • 金额:
    $ 39.35万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-02-15 至 2016-01-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Toxoplasma gondii is an intracellular protozoan parasite that has a worldwide distribution. Depending on the geographic area, 30-70% of the human population is infected with this parasite, and essentially the entire human population is at risk of infection. This obligate parasite is usually responsible for multi-organ failure only in immunocompromised individuals, especially those afflicted with AIDS, but if infection with T. gondii occurs during pregnancy, abortion or fetal abnormalities often occur. The combined efforts of IL-12 and IFN- are central to resistance to T. gondii. We have recently established that TLR11 plays a dominant role in sensing T. gondii, regulating IL-12 production, and activating T cell-mediated responses to the parasite. Concomitantly, TLR11 is represented in humans only by a non-functional pseudogene, and the major question of how human innate and adaptive immune responses occur in the absence of TLR11 remains unanswered. The overall goals of this project are 1) to determine the roles of neutrophils, macrophages, and DCs in the regulation of TLR11-independent induction of IL-12; 2) to determine the roles of NK, CD4, and CD8 T cells in IFN--dependent host resistance to T. gondii in the absence of TLR11; and 3) to identify similarities and differences during systemic and mucosal TLR11-independent immune responses to T. gondii. These studies are expected to identify mechanisms of TLR11-independent host resistance to T. gondii. In addition, these studies are essential for establishing animal models suitable for the design of protective vaccines against T. gondii, and possibly against other apicomplexan parasites.
描述(由申请人提供):弓形虫Gondii是一种具有全球分布的细胞内原生动物寄生虫。根据地理区域的不同,30-70%的人口感染了这种寄生虫,从本质上讲,整个人口都有感染的风险。这种强制性寄生虫通常仅在免疫功能低下的个体中造成多器官失败,尤其是患有艾滋病的人,但是如果在怀孕期间出现T. gondii的感染,经常发生堕胎或胎儿异常。 IL-12和IFN-的综合努力是对巨杆菌抗性的核心。我们最近确定,TLR11在传感t. gondii,调节IL-12产生并激活T细胞介导的对寄生虫的反应中起着主要作用。同时,TLR11仅以非功能性假基因为代表,而在没有TLR11的情况下,人类先天和适应性免疫反应如何发生的主要问题仍未得到解答。该项目的总体目标是1)确定中性粒细胞,巨噬细胞和DC在TLR11独立诱导IL-12诱导中的作用; 2)在没有TLR11的情况下,确定NK,CD4和CD8 T细胞在IFN依赖性宿主对T. gondii的抗性中的作用; 3)在全身和粘膜TLR11无依赖性的免疫反应中确定相似性和差异。这些研究有望确定与TLR11无关的宿主对T. gondii的抗性的机制。此外,这些研究对于建立适合于针对gondii的保护性疫苗的动物模型至关重要。

项目成果

期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
T-bet-independent Th1 response induces intestinal immunopathology during Toxoplasma gondii infection.
  • DOI:
    10.1038/mi.2017.102
  • 发表时间:
    2018-05
  • 期刊:
  • 影响因子:
    8
  • 作者:
    López-Yglesias AH;Burger E;Araujo A;Martin AT;Yarovinsky F
  • 通讯作者:
    Yarovinsky F
Innate responses to Toxoplasma gondii in mice and humans.
  • DOI:
    10.1016/j.pt.2011.03.009
  • 发表时间:
    2011-09
  • 期刊:
  • 影响因子:
    9.6
  • 作者:
    Pifer, Reed;Yarovinsky, Felix
  • 通讯作者:
    Yarovinsky, Felix
Microbial infection-induced expansion of effector T cells overcomes the suppressive effects of regulatory T cells via an IL-2 deprivation mechanism.
  • DOI:
    10.4049/jimmunol.1100769
  • 发表时间:
    2012-01-15
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Benson A;Murray S;Divakar P;Burnaevskiy N;Pifer R;Forman J;Yarovinsky F
  • 通讯作者:
    Yarovinsky F
共 3 条
  • 1
前往

Felix Yarovinsky的其他基金

Mucosal immunity to Toxoplasma gondii
对弓形虫的粘膜免疫
  • 批准号:
    9472557
    9472557
  • 财政年份:
    2018
  • 资助金额:
    $ 39.35万
    $ 39.35万
  • 项目类别:
Mucosal immunity to Toxoplasma gondii
对弓形虫的粘膜免疫
  • 批准号:
    9913455
    9913455
  • 财政年份:
    2018
  • 资助金额:
    $ 39.35万
    $ 39.35万
  • 项目类别:
Mucosal immunity to Toxoplasma gondii
对弓形虫的粘膜免疫
  • 批准号:
    10390295
    10390295
  • 财政年份:
    2018
  • 资助金额:
    $ 39.35万
    $ 39.35万
  • 项目类别:
Neutrophil IFN-gamma in host defense and inflammation
中性粒细胞 IFN-γ 在宿主防御和炎症中的作用
  • 批准号:
    9433503
    9433503
  • 财政年份:
    2016
  • 资助金额:
    $ 39.35万
    $ 39.35万
  • 项目类别:
Neutrophil IFN-gamma in host defense and inflammation
中性粒细胞 IFN-γ 在宿主防御和炎症中的作用
  • 批准号:
    9106433
    9106433
  • 财政年份:
    2016
  • 资助金额:
    $ 39.35万
    $ 39.35万
  • 项目类别:
Cellular and molecular mechanisms of host resistance to Toxoplasma gondii
宿主抵抗弓形虫的细胞和分子机制
  • 批准号:
    7901942
    7901942
  • 财政年份:
    2010
  • 资助金额:
    $ 39.35万
    $ 39.35万
  • 项目类别:
Cellular and molecular mechanisms of host resistance to Toxoplasma gondii
宿主抵抗弓形虫的细胞和分子机制
  • 批准号:
    8423397
    8423397
  • 财政年份:
    2010
  • 资助金额:
    $ 39.35万
    $ 39.35万
  • 项目类别:
Cellular and molecular mechanisms of host resistance to Toxoplasma gondii
宿主抵抗弓形虫的细胞和分子机制
  • 批准号:
    8025969
    8025969
  • 财政年份:
    2010
  • 资助金额:
    $ 39.35万
    $ 39.35万
  • 项目类别:
Cellular and molecular mechanisms of host resistance to Toxoplasma gondii
宿主抵抗弓形虫的细胞和分子机制
  • 批准号:
    8212630
    8212630
  • 财政年份:
    2010
  • 资助金额:
    $ 39.35万
    $ 39.35万
  • 项目类别:
Molecular pathways involved in TLR11 mediated IL-12 production by dendritic cells
TLR11 介导树突状细胞产生 IL-12 的分子途径
  • 批准号:
    7509644
    7509644
  • 财政年份:
    2008
  • 资助金额:
    $ 39.35万
    $ 39.35万
  • 项目类别:

相似海外基金

Developing Cyclopeptide Nef Inhibitors to Facilitate HIV-1 Eradication
开发环肽 Nef 抑制剂以促进 HIV-1 根除
  • 批准号:
    10759561
    10759561
  • 财政年份:
    2023
  • 资助金额:
    $ 39.35万
    $ 39.35万
  • 项目类别:
Investigating MHC-I downregulation by HIV-1 Nef using cryo-electron tomography with laser-based phase contrast
使用基于激光相差的冷冻电子断层扫描研究 HIV-1 Nef 对 MHC-I 的下调
  • 批准号:
    10607448
    10607448
  • 财政年份:
    2023
  • 资助金额:
    $ 39.35万
    $ 39.35万
  • 项目类别:
Developing Cyclopeptide Nef Inhibitors to Facilitate HIV-1 Eradication
开发环肽 Nef 抑制剂以促进 HIV-1 根除
  • 批准号:
    10652729
    10652729
  • 财政年份:
    2022
  • 资助金额:
    $ 39.35万
    $ 39.35万
  • 项目类别:
Mechanisms of host leukocyte-mediated Toxoplasma dissemination in its host
宿主白细胞介导的弓形虫在宿主体内传播的机制
  • 批准号:
    10623334
    10623334
  • 财政年份:
    2022
  • 资助金额:
    $ 39.35万
    $ 39.35万
  • 项目类别:
Disruption of Type I Interferon Induction by a KSHV Homologue of IPS-1
IPS-1 的 KSHV 同系物对 I 型干扰素诱导的破坏
  • 批准号:
    10258718
    10258718
  • 财政年份:
    2021
  • 资助金额:
    $ 39.35万
    $ 39.35万
  • 项目类别: